| P2093 | author name string | Mackiewicz A | |
| | Nawrocki S | |
| | Wysocki PJ | |
| P2860 | cites work | Identification of human cancers deficient in antigen processing | Q24678495 |
| | CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation | Q24678846 |
| | Dendritic cells and the control of immunity | Q27860918 |
| | Tolerance, danger, and the extended family | Q29547532 |
| | Replicative adenoviruses for cancer therapy | Q33963944 |
| | Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 |
| | Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 |
| | Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology | Q35470135 |
| | A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal | Q35915922 |
| | Inducing autoimmune disease to treat cancer | Q35976297 |
| | Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens | Q36359942 |
| | In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression | Q36362939 |
| | Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes | Q36363449 |
| | Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function | Q36363597 |
| | Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. | Q36368332 |
| | Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo | Q36375248 |
| | The central role of CD4(+) T cells in the antitumor immune response | Q36401381 |
| | Cytokine secretion patterns and cross-regulation of T cell subsets | Q36440960 |
| | Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma | Q36639818 |
| | Study of antibodies against human melanoma produced by somatic cell hybrids | Q37590914 |
| | Structure, function, and clinical significance of human tumor antigens | Q38002574 |
| | Unique tumor-specific antigens | Q39647347 |
| | The B7 and CD28 receptor families | Q40392461 |
| | Fas and Fas ligand: lpr and gld mutations | Q40398275 |
| | T-cell activation: integration of signals from the antigen receptor and costimulatory molecules | Q40422805 |
| | Signals and signs for lymphocyte responses | Q40620206 |
| | Natural history of HLA expression during tumour development. | Q40797268 |
| | Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line | Q40888195 |
| | Differential regulation of murine T lymphocyte subsets | Q40898191 |
| | Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 |
| | Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector | Q41083246 |
| | BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes | Q41371291 |
| | Soluble interleukin 6 receptor is biologically active in vivo | Q41374774 |
| | Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 | Q41589138 |
| | Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity | Q41719324 |
| | Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response | Q41744259 |
| | Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy | Q44532957 |
| | Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells | Q44615042 |
| | Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma | Q45880359 |
| | The wisdom of hindsight. | Q45993248 |
| | Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 |
| | Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells | Q57275942 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 193-204 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer | |
| P478 | volume | 1 | |